Q1 EPS Estimates for Urogen Pharma Raised by HC Wainwright

Urogen Pharma (NASDAQ:URGN) – HC Wainwright increased their Q1 2026 EPS estimates for Urogen Pharma in a research note issued to investors on Tuesday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.60) per share for the quarter, up from their previous forecast of ($0.63). The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.99) EPS and FY2027 earnings at $0.45 EPS.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million.

URGN has been the subject of several other reports. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.29.

Urogen Pharma Stock Up 7.1%

URGN opened at $20.16 on Thursday. The company’s 50-day moving average price is $21.03 and its 200 day moving average price is $20.87. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $30.00. The firm has a market cap of $981.43 million, a price-to-earnings ratio of -6.30 and a beta of 1.34.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of URGN. Osaic Holdings Inc. raised its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares in the last quarter. State of Wyoming acquired a new position in shares of Urogen Pharma in the third quarter worth about $66,000. Russell Investments Group Ltd. increased its position in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after acquiring an additional 3,125 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Urogen Pharma during the third quarter valued at approximately $76,000. Institutional investors own 91.29% of the company’s stock.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the transaction, the insider directly owned 144,985 shares of the company’s stock, valued at $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 7,479 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the transaction, the general counsel owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This trade represents a 12.72% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by company insiders.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.